Objectives: Ceftaroline, a broad-spectrum cephalosporin, has activity against Gram-positive and several Gram-negative bacteria (GNB). This study aimed to evaluate the antimicrobial activity of ceftaroline and comparators against isolates causing skin and soft tissue infections (SSTIs) and respiratory tract infections (RTIs) collected in Latin America (LATAM) in 2016-2020 as part of the Antimicrobial Testing Leadership and Surveillance program (ATLAS).
Methods: Minimum inhibitory concentrations were determined using both Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria.
Results: Ceftaroline demonstrated potent activity against methicillin-susceptible Staphylococcus aureus (CLSI/EUCAST: MIC 0.25 mg/L; susceptibility 100%), whereas activity against methicillin-resistant S. aureus varied for SSTIs (MIC 1 mg/L; susceptibility 92.5%) and RTIs isolates (MIC 2 mg/L; susceptibility 72.9%) isolates. For Streptococcus pneumoniae, particularly penicillin-resistant isolates commonly causing respiratory infections, high ceftaroline activity (MIC 0.25 mg/L; susceptibility 100%/98.4%) was noted. All isolates of β-hemolytic streptococci were susceptible to ceftaroline (S. agalactiae: MIC 0.03 mg/L [SSTIs]; MIC 0.015 mg/L (RTIs); susceptibility 100%; S. pyogenes: MIC 0.008 mg/L; susceptibility 100%). Ceftaroline was highly active against Haemophilus influenzae, including β-lactamase positive isolates (MIC 0.06 mg/L; susceptibility 100%/85.7%). Ceftaroline demonstrated high activity against non-ESBL-producing GNB (E. coli: MIC 0.5 mg/L, susceptibility 91.9%; K. pneumoniae: MIC 0.25 mg/L, susceptibility 95.1%; K. oxytoca, MIC 0.5 mg/L; susceptibility 95.7%).
Conclusion: Ceftaroline was active against the recent collection of bacterial pathogens commonly causing SSTIs and RTIs in LATAM. Local and regional surveillance of antimicrobial resistance patterns are crucial to understand evolving resistance and guide treatment management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jgar.2023.11.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bacterial contamination in public transport during COVID-19 pandemic: Characterization of an unusual Staphylococcus aureus isolate tolerant to vancomycin.
Ecotoxicol Environ Saf
January 2025
Department of Medical Microbiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Czech Republic. Electronic address:
Public transport represents a potential site for the transmission of resistant pathogens due to the rapid movement of large numbers of people. This study aimed to investigate the bacterial contamination of frequently touched surfaces in the public transport system operating in the proximity of the biggest Czech hospital during the coronavirus pandemic despite extensive cleaning and disinfection efforts. In June and September 2020, samples from the metro trains, ground transport and stationary objects were collected, enriched and cultured.
View Article and Find Full Text PDFIn vitro activity of cefepime-tazobactam against oxyimino cephalosporin-resistant clinical isolates of E. coli: exploring a potential carbapenem-sparing strategy.
Eur J Clin Microbiol Infect Dis
January 2025
Department of Medical Microbiology, PGIMER, Chandigarh, Chandigarh, 160012, India.
Cefepime-tazobactam (FEP-TAZ) consists of cefepime combined with tazobactam, a penicillanic acid-sulfone recognized as an established beta-lactamase inhibitor. This study aims to investigate the in-vitro effectiveness of FEP-TAZ against cefepime-resistant clinical isolates of Escherichia coli (E. coli).
View Article and Find Full Text PDFClinical and microbiological analyses of colistin-resistant strains among carbapenem-resistant complex clinical isolates.
Microbiol Spectr
December 2024
Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Carbapenem-resistant complex (CR-ECC), which is rapidly increasing as the cause of nosocomial infections, has limited treatment options. The aim of this study is to investigate the microbiological and clinical traits and molecular epidemiology of isolates of CR-ECC and provide guidance for antibiotic selection in clinical practice. Clinical CR-ECC isolates (ertapenem MIC ≥ 2 mg/L) were collected from 2021 to 2022.
View Article and Find Full Text PDFMitigating salinity stress on tomato growth, water regime, gas exchange, and yield with the application of QuitoMax.
Sci Rep
December 2024
Department of Crop and Animal Production, Safiye Cikrikcioglu Vocational College, Kayseri University, Kayseri, Türkiye.
This study assessed the intensity of salt stress in the two tomato varieties by measuring variables associated with the water regime, chlorophyll content, normalized difference vegetation index, gas exchange, and yield. The cultivars Amalia and Claudia, which represent tolerance and susceptibility to salinity, were evaluated. Three treatments were established in plastic pots, using a completely randomized design: T1, saline soil (ECse = 6.
View Article and Find Full Text PDFIn vitro susceptibility of 147 international clinical Mycobacterium abscessus isolates to epetraborole and comparators by broth microdilution.
J Antimicrob Chemother
December 2024
Division of Mycobacterial and Respiratory Infections, Department of Medicine, National Jewish Health, Denver, CO, USA.
Background: Mycobacterium abscessus is a highly drug-resistant non-tuberculous mycobacterium (NTM) for which treatment is limited by the lack of active oral antimycobacterials and frequent adverse reactions. Epetraborole is a novel oral, boron-containing antimicrobial that inhibits bacterial leucyl-tRNA synthetase, an essential enzyme in protein synthesis, and has been shown to have anti-M. abscessus activity in preclinical studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!